Nivolumab plus ipilimumab in the treatment of advanced melanoma

Journal of Hematology & Oncology

Adil I. Daud¹  Katy K. Tsai¹ 

[1] Helen Diller Comprehensive Cancer Center, University of California, 1600 Divisadero St., San Francisco 94115, CA, USA

关键词: Ipilimumab;    Nivolumab;    CTLA-4;    PD-1;    Immunotherapy;    Melanoma;   

Others  :  1233268
DOI  :  10.1186/s13045-015-0219-0

 received in 2015-08-21, accepted in 2015-10-13,  发布年份 2015

【 摘 要 】

Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting developments, there remains room for improvement in treatment outcomes. Combination immunotherapy, in particular combined cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) blockade, represents an important first step in this direction.

【 授权许可】

   
2015 Tsai and Daud.

【 参考文献 】

• [1]Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995; 182:459-65.
• [2]Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 1996; 183:2533-40.
• [3]Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11:3887-95.
• [4]Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 2013; 14:1212-8.
• [5]Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. 2010; 107:4275-80.
• [6]Selby M, Engelhardt H, Lu L-S, Quigley M, Wang C, Chen B, et al. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J Clin Oncol 31, 2013(suppl;abstr 3061).
• [7]Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H et al.. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 2015; 194:950-9.
• [8]Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM et al.. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013; 369:122-33.
• [9]Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D et al.. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015; 372:2006-17.
• [10]Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015; 373:23-34.
• [11]Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al.. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363:711-23.
• [12]Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C et al.. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011; 364:2517-26.
• [13]Robert, C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2014. doi:10.1056/NEJMoa1412082.
• [14]Weber JS, Minor D, D’Angelo SP, Hodi FS, Gutzmer R, Bart N et al.. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choicechemotherapy (ICC) in patients with advanced melanoma with prior anti-CTLA-4 therapy. 2014. abstract
• [15]Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014; 7:70. BioMed Central Full Text
• [16]Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol. 2014;32(5s).